Tesamorelin

Overview

Tesamorelin is unique among growth hormone-releasing peptides: it is the only GHRH analog with an FDA-approved indication. Approved in November 2010 under the brand name Egrifta (and later Egrifta SV and Egrifta WR), it is indicated for the reduction of excess abdominal fat in people with HIV-associated lipodystrophy — a condition involving abnormal visceral fat accumulation.

That regulatory history matters: because tesamorelin went through the full FDA process, it has larger, higher-quality randomized controlled trial data than essentially any other growth hormone secretagogue (CJC-1295, ipamorelin, sermorelin, etc.), none of which have an approved human indication.

Mechanism

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically a stabilized form of GRF(1–44). Its mechanism is a three-step cascade:

1. Binds pituitary GHRH receptors, stimulating the gland to release the body's own growth hormone.
2. Increases endogenous, pulsatile GH secretion — preserving the natural rhythm and feedback loops, rather than supplying a constant exogenous GH level.
3. Raises serum IGF-1 and IGFBP-3, which mediate the downstream anabolic and lipolytic effects, with a particular tendency to reduce visceral adipose tissue (VAT).

Because it works through the pituitary, tesamorelin maintains physiologic feedback — a key theoretical safety advantage over injecting recombinant GH directly.

Key Research Areas

Visceral fat — the approved indication

The FDA registration rested on two large, identically designed Phase 3 trials by Falutz and colleagues:

• NEJM 2007 (n≈412, 26 weeks): tesamorelin reduced VAT by approximately 15%, while placebo VAT increased ~5% — a substantial between-group difference. Lean mass was preserved and triglycerides improved.
• JAIDS 2010 (the second pivotal trial plus a safety extension): confirmed the VAT reduction and characterized the safety profile over a longer period, including the reversibility of effect on discontinuation.

A defining feature: the fat loss is preferentially visceral, not subcutaneous, which is the metabolically dangerous fat depot.

Liver fat / NAFLD

Later work by Stanley and colleagues extended tesamorelin's evidence base to the liver:

• JAMA 2014: a randomized trial showing tesamorelin reduced both visceral fat and liver fat (net hepatic fat reduction versus placebo).
• Lancet HIV 2019 (n=61, 12 months): in HIV-associated NAFLD, tesamorelin reduced hepatic fat fraction by roughly a third in relative terms and attenuated progression of liver fibrosis — a clinically meaningful endpoint.

This positions tesamorelin as one of relatively few agents with randomized evidence for reducing liver fat.

Body composition and the GH/IGF-1 axis

Because it raises GH and IGF-1, tesamorelin is studied off-label for body composition (visceral fat reduction with lean-mass preservation). The trade-off is that GH-axis stimulation can reduce insulin sensitivity and raise glucose, so glycemic monitoring is standard, particularly in anyone pre-diabetic.

A note on cognition: older literature explored GHRH analogs and cognitive function in aging, but a tesamorelin-specific, well-verified cognition trial is not firmly established and should not be cited as settled. Earlier versions of this profile overstated this — the durable, verifiable evidence for tesamorelin is in visceral fat and liver fat.

vs. CJC-1295 and Other GH Peptides

| Feature | Tesamorelin | CJC-1295 / Ipamorelin | |---|---|---| | FDA-approved indication | Yes (HIV lipodystrophy) | No | | Large RCT evidence | Yes | No | | Mechanism | GHRH analog | GHRH analog / ghrelin mimetic | | Validated endpoint | Visceral & liver fat | None clinically validated |

Many researchers favor tesamorelin precisely because of its validated mechanism, real trial data, and predictable dosing, even though peptides like CJC-1295 offer longer dosing intervals.

Dosing Note

The common shorthand "2 mg daily" refers to the vial strength, not the delivered dose. The approved formulations actually deliver 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR) subcutaneously once daily, injected into the abdomen with site rotation. This distinction matters when interpreting protocols.

Bottom Line

Tesamorelin is the most evidence-backed growth hormone-releasing peptide available, with FDA approval and multiple randomized trials behind it — but that evidence is specifically in HIV-associated visceral fat and liver fat. Use outside that population is off-label, long-term cardiovascular safety is not established, and the GH-axis effects on glucose warrant monitoring.